Podcast appearances and mentions of Mark Roberts

Christmas Day: Matthew 4:1-17 - Mark Roberts - 25.12.25 by Wollongong Baptist Church

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this 8-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.Mark Roberts, MDUndoubtedly, the immune system is a major issue in these patients. It would be fantastic if we could immunotolerize our patients and indeed prevent the rejection of the therapy. We've talked about the fact that these are viral vectors and of course there may be high seroprevalence of antibodies to these viral vectors, and it's very important in the pre-screening of patients who might be eligible to understand that at the beginning. These of course can have developed over the years and of course can be part of immunological memory and therefore extremely difficult and probably impractical to actually shift.On giving the treatment though as I think we're all aware there is this problem of the innate immunity and potential therefore for acute toxicities and then a learned or adaptive response with cytotoxic T cells and antibodies which may of course become high tighter neutralizing antibodies and potentially antibodies not only against the viral vector, even the functional protein, even the transgene are all theoretical possibilities with time. The capsid, the transgene, and even the protein product can all potentially induce an immunological event. Of course, all of these would lead to both potential patient changes and then a lack of efficacy of the treatment.Indeed, there have been some serious and indeed fatal problems in the gene therapy development program as I think we're all aware. Though many of these are thankfully been overcome. Spinal muscular atrophy has a gene therapy which is licensed, but there were early patients who actually had significant problems. A patient of just 6 months of age who developed kidney failure, two other patients who actually developed liver failure.In Duchenne muscular dystrophy, a very common condition, again there were significant issues and crucially in these patients who all have cardiomyopathy, it was heart failure and cardiac arrest that were big concerns and pulmonary edema and this was seen even with a CRISPR-based technology and is perhaps is best known but has been addressed the excellent myotubular myopathy patients, four patients died and crucially quite a long time after the gene therapy emphasizing the need to monitor these patients extremely carefully and these patients died of cholestatic liver failure albeit that they had a degree of liver dysfunction.That's changed our screening of course of patients, we're now all looking in myotubular patients for liver involvement and Rett syndrome as well. Now these immunoprophylaxis treatment regimes to hopefully try and reduce the immunological reaction against the gene are certainly evolving.This is just a summary of some of the other immunosuppressive regimes used in other disorders, for example, spinal muscular atrophy, but Pompe and MPS as examples of LSDs. Certainly these regimes will continue to evolve and are going to be very important in seeking to make sure that these treatments are effective. It reminds me somewhat of what's happened with enzyme replacement therapy that the use of these immunological strategies in infants has revolutionized the utility of those treatments in early patients.In the next part, Dr. Roberts will discuss lessons learned from gene therapy trials.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs.Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lessons learned from gene therapy trials.Mark Roberts, MDWhen we think about the challenges of actually doing clinical trials with these gene therapies, there's a huge development stage in terms of picking the right viral vector with the right surface receptor. That's a major piece of work. That can often take years. The preclinical work is obviously very important as indeed is understanding the natural history because it's really not practical to do placebo-controlled trials of gene therapies.In contrast to other studies, when we turn to phase 1 and phase 2, you'll notice that the patient numbers are often quite small. One is having to think carefully about surrogate measurements of response. Especially when in phase 3 studies, we may be thinking about withdrawing the existing, for example, enzyme replacement therapy because we believe the gene therapy will then be effective.That's just a few snapshots of where we've come and there's a lot more work to be done.In the next part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at WORLDSymposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.Nicola Longo MD, PhDWhat I want to do today, is just place gene replacement therapy within the current landscape of lysosomal storage disorder treatment therapy. Gene therapy obviously has the potential of treating lysosomal disorder to correct the root cause of lysosomal storage disorder. The gene is defective, and what happen is that you can potentially either fix the gene or bypass the lack of the genetic product. But there are already therapies that are existing and are functioning. Obviously, in many cases, the lysosomal disorder is caused by defective production of an enzyme, which is defective.We can either replace the enzyme with enzyme replacement therapy, or provide chaperone for specific mutations that retain the synthesis of the enzyme, that however is not very functional. Another avenue that it is being reported is the utilization of substrate reduction therapy. A substrate accumulates, you prevent the synthesis of the substrate to reduce the accumulation of toxic material. What we know now is that this is not enough to produce many lysosomal disorders. In many cases, the lysosomal disorder result sometime in impairment of intracellular trafficking, and sometime in the function of other organelles.At the end, it results in the activation of the macrophagic system and inflammation. Already we have some therapy acting at this level. The end result of lysosomal storage disorder, there will be cell suffering and cell death, leading to a progression of the disease, and morbidity and mortality. Now, what therapy do we have available already? Obviously, hematopoietic stem cell transplantation has been around for quite some time.It has been the same thing that we do with gene therapy, except that instead of reintroducing the gene of the subject, we place gene of a subject who is not affected of the disease. This therapy has been proven effective in cases of MPS-1 and alpha-mannosidosis. But in many cases this has to be given way before symptoms start to be affected.Enzyme replacement therapy has been around for quite some time, starting with Gaucher disease, and now that it is available for a list of diseases that are there, so it's like Fabry, Gaucher, Pompe, different types of mucopolysaccharidosis, alpha-mannosidosis, acid lipase deficiency, 1 neuronal ceroid lipofuscinosis, and Niemann-Pick type A and B.Obviously the advantage of this therapy, they give back the enzyme that it is defective. But the disadvantage that many time they cannot enter specialized areas such as the brain. There is already the second generation of enzyme replacement therapy that it is available. With this second generation, some of the newer drugs are more effective in terms of cellular uptake, or in terms of having a prolonged half-life and prolonged activity.Then there are pharmacological chaperone therapy, and the one which is FDA approved is migalastat for Fabry disease, under study is ambroxol for Gaucher disease. The disadvantage of this therapy that only a selected number of mutations respond to this therapy.Substrate reduction therapy has been introduced for Gaucher disease many years ago with miglustat, and it was followed by eliglustat. Both of them are effective, and some of them more effective than other, simply because of the fewer side effects of eliglustat as compared to miglustat. But at the same time, eliglustat does not pass the blood brain barrier.Finally, the newer agents that are already administered, N-acetyl-L-leucine and arimoclomol, both approved for Niemann-Pick type C, they act more on the downstream effect of the lysosomal storage disorder, either by stabilizing neuronal cell activity or by reducing the inflammation that is present in the brain.In the next part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Doctors Roberts and Longo will discuss treatment with gene therapies.Question: Can one administer AAV-mediated gene therapy repeatedly?Mark Roberts, MDI think the traditional view would have been no. One can think of gene therapy as a silver bullet. Hopefully, it will reach its target. But if it's not effective, that bullet has been shot, the immunological response has occurred, and it means redosing, at least with that particular vector, may become difficult. But this situation is changing and evolving as we have better understanding of immunological modulation for repeat testing. We were discussing this yesterday evening, weren't we, Professor Longo?Nicola Longo MD, PhDCorrect. Basically, the current AAV-based gene therapy cannot be readministered. It is either effective, or it doesn't work. The other thing is that even though in theory, one could utilize a different AAV vector with different immunogenicity, there is many times cross-reactivity among the different adenovirus, adeno-associated viruses. Now, there are approaches in animal models in which you give a strong immune suppression to prevent the creation of the immune response against the adeno-associated virus, and at least in the animal model, it has been possible to give some of the gene therapy repeatedly.The second approach that is being tested is with gene correction therapy, in which by using an RNA guide and the CRISPR/Cas9 system delivered by lipid nanoparticles, you basically correct some of the effective genetic information. Obviously, since this is done by lipid nanoparticles and not by an AAV, the immunity that you create is really not there. You can give this one repeatedly, and in theory, it can be given more than one time. But again, you are absolutely correct. The current gene therapy cannot be given twice, and either it works or it doesn't work.Question:vWill gene-therapy-treated patients be able to go back to the standard of care or enzyme replacement therapy?Mark Roberts, MDI think when we're talking to patients about the potential benefits of gene therapy and the amelioration of the requirement to have these infusions on a regular basis of ERT, the hope is that will work, but they need to be reassured that we can potentially go back to the ERT. Gene therapy is an important treatment, but we don't know the destination of the patient at the beginning, and we have to make it available to them to go back to ERT.One of the crucial questions, of course, though, is the basis of the immunological reaction that perhaps prevented the gene therapy being effective. If it's against the viral vector, well, okay. If it's against the transgene, not great. If it's against the functional protein, that becomes more difficult. It is somewhat, I think at this time, to be fair to say to patients, think of gene therapy as a trial treatment. It is somewhat a leap of faith and an important observation, of course, for the patient community, but just be aware there may be downsides.Nicola Longo MD, PhDThey totally agree with Dr. Roberts. In general, they should be able to go back to enzyme replacement therapy if the gene therapy is not effective. However, what we are starting to appreciate is that we need to understand the immune response, not just to the enzyme replacement therapy, but also to gene therapy. What this field is doing is forcing geneticists to deal with the immune response. I feel that historically has not been dealt together. The two things need to be integrated. The advantage of the gene therapy is that the protein is produced endogenously. There should be the development of some degree of tolerance with time in the body towards the endogenous continuous production of a protein.Now, will that happen all the time? I still do not know. Again, we need to understand much better what is the integration of the immune system with the response to gene therapy in the ongoing clinical trials.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lysosomal disorders and the potential for gene therapies.Mark Roberts, MDI'm going to give an overview of what is gene therapy, emphasizing the current challenges and the development issues and needs that there will be as we try and enable gene therapy for our patients, particularly those with lysosomal storage disorders.I'm going to try and make a case for why lysosomal storage disorders are an extremely good group of conditions for the potential benefits of gene modifying therapies. Firstly, whilst we all recognize that these conditions are inherently individually rare, they're certainly severe. Collectively, with over 70 LSD disorders, 1 in 5,000 may be afflicted by these conditions ultimately in their life and can be detected, for example, by newborn screening programs.Secondly, there's certainly a significant clinical burden with these patients with the current standard of care, so a large unmet need exists. Existing enzyme replacement therapies have undoubtedly changed the natural history of many of these conditions, but there are limitations and often initial benefits and later deteriorations.Unfortunately, for most lysosomal storage disorders, it's only symptomatic treatments and indeed, care that is available for these patients with no specific treatment. Thirdly, these conditions are extremely well-characterized, monogenic singleton and problems of inborn errors of metabolism. We know the functional protein that is deficient in these conditions. Because of that, and knowing that these are critical for lysosomal function, and using preclinical models, we can model the potential benefits of gene therapies very well in a number of systems, including, of course, soon, muscle chip experiments as well.Finally, with these conditions, they may potentially be really useful targets whilst not perhaps curing the condition, at least ameliorating the phenotype, and enabling the addition of other treatments as well, potentially. I've noted, some of these therapies can be directly delivered to certain tissues, so muscle tissue, which is my main interest, but also, crucially, the central nervous system, which is very important when we consider ameliorated phenotypes, for example, treated by enzyme replacement therapy, but where the children who become the adults have significant learning disability as a major component to their problems.In the next part, Dr. Roberts will discuss vectors, different strategies, modes of administration, and targets in gene replacement therapies.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Awaiting the Day: 1 Thessalonians 5:1-11 - Mark Roberts - 23.11.25 by Wollongong Baptist Church

Linda Ronstadt - Tumbling DiceAmii Stewart - Knock On Wood (Dr Packer Remix Edit)The Trammps - Disco Inferno (Dr Packer Remix Edit)Jocelyn Brown - Ain't No Mountain High Enough (Dr Packer Remix Extended)Quincy Jones - Ai No Corrida (Dr Packer Remix Extended)Dead Or Alive - You Spin Me Round (Dr Packer Remix Extended)D.C. LaRue - Cathedrals (Dr Packer Remix)Eminem Ft Nate Dogg - Shake ThatEd Sheeran - Eyes Closed (ULTI-reMIX by Beat Thrillerz)Various Artists -  The 2003 Flashback MedleyDavid Guetta & Showtek - Your Love (Ultimix by Beat Thrillerz)Debbie Gibson - Only In My Dreams (Ulti-Remix By Mark Roberts)Eurythmics - Sweet DreamsNicki Minaj - Starships (ULTI-kwikMIX by Stacy Mier)Bon Jovi - Livin' On A Prayer (ULTI-reMIX by DJ Brian Howe)R3hab, Mufasa & Hypeman & Rani - Believe (Shooting Stars) (Ultimix By Stacy Mier)Katy Perry - Last Friday Night (Ultimix by Stacy Mier)Meghan Trainor - Made You Look - Pt2 (Ulti-Remix By Beat Thrillerz)Earth Wind & Fire - September (Ultimix by Mark Roberts)Big Country - In A Big Country (Ulti-Remix By Beat Thrillerz)Afrika Bambaataa And Family Ft. UB40 - Reckless (Vocal Wildstyle Mix)Yvonne Elliman - If I Can't Have YouAnita Ward - Ring My BellAlexandra Stan - Mr. Saxobeat (Ultimix by Mark Roberts)Lotus, Spyzr & Salt-N-Pepa - Push It (Ultimix)Boney M - Rasputin (Ultimix By Mark Roberts)Rednex - Cotton Eye Joe (Ultimix by Will Faircloth & Tim Robertson)The Dazzband - Swoop! I'm YoursDavid Guetta Ft Anne-Marie & Coi Leray - Baby Don't Hurt Me (Ultimix by Stacy Mier) David Guetta Ft Bebe Rexha - I`m Good (Blue) (Oliver Heldens Extended Remix)Men At Work - Who Can It Be Now (Ulti-Remix By Mark Roberts)Neil Diamond - Sweet Caroline (Ultimix by Stacy Mier)Pat Benatar - Hit Me with Your Best Shot (Ulti-Remix by Josh Harris)Flo Rida Feat. T-Pain - Low (Funkymix by Dave Jackson)Zedd & Liam Payne  - Get Low (DJ Beats)Rihanna - Only Girl (In The World)Rihanna - S&MRick James - SuperfreakRihanna - We Found LoveTag Team - Whoomp There It IsThe Proclaimers - Im Gonna Be (500Miles)PSY vs MC Hammer - Gangnam Style  2 Legit 2 Quit mashup (Funkymix by Stacy Mier)Billy Idol - Mony Mony (Clean - Idol/Stevens Mix) (Back Spins by Mark Roberts)

Greg and Dan talk to Scott Witzig and Mark Roberts of the Morton Community Foundation about their 111-year-old organization and its long-standing commitment to strengthening local communities. They share how the foundation is powered by people who love to give back, want to make a difference, and believe deeply in investing in the future. Scott and Mark talk about the growth, generosity, and positive change they’ve seen over the years, the importance of caring for community assets, and their optimism for the year ahead. They also highlight how collaboration and new partnerships continually expand the impact of their work. For more information, visit www.mortoncommunityfoundation.orgSee omnystudio.com/listener for privacy information.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Awaiting the Day: 1 Thessalonians 4:13-18 - Mark Roberts - 16.11.25 by Wollongong Baptist Church

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Ann talks with Mark Roberts, PA-C, and Dr. Crawford Allison (both of Patient First Direct Primary Care), about their system and health care in central Texas. Next, Ann talks with Dr. Marilyn Goodman, BSN, BSA, DC (of Altrusa International of The Brazos and hotchiropractic.com) about the upcoming Central Texas Turkey Trot. Finally, we get Act Locally Waco from Elizabeth Riley. Learn more about your ad choices. Visit megaphone.fm/adchoices

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the reading materialClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Welcome to Paranormal Spectrum, where we illuminate the enigmatic corners of the supernatural world. I'm your host, Barnaby Jones, and today we have a very special guest joining us:Founded in 2017 by husband and Wife Billy and Jill WinsettNight Vision Paranormal is a family owned and operated paranormal investigation group based out of western KY. Night Vision paranormal investigates everything paranormal including ghosts, aliens, and cryptids. The team also consists of Jills father Mark Roberts who heads up the cryptid division and Skyler Winsett (Billy and Jills oldest son) Night Vision Paranormal also has a JR division that consist of Billy and Jills younger children. In 2024 Night Vision Paranormal expanded from investigations to also include vending and speaking at local cons and festivals. They have investigated Waverly Hills Sanatorium in Louisville Ky, Ashmore Estates in Ashmore Il, The Glenn House in Cape Girardeau Mo. As well as several other renowned and historical locations and many local homes and businesses in and around Western KY and Surrounding states.You can find Night Vision Paranormal on facebook and tik tok.https://www.facebook.com/share/16dCsaBPXy/?mibextid=wwXIfrhttps://www.tiktok.com/@nvp_wkynightvisionparanormalky@gmail.comClick that play button, and let's unravel the mysteries of the UNTOLD! Remember to like, share, and subscribe to our channel to stay updated on all the latest discoveries and adventures. See you there!Join Barnaby Jones on the Paranormal Spectrum every Thursday on the Untold Radio Network Live at 12pm Central – 10am Pacific and 1pm Eastern. Come and Join the live discussion next week. Please subscribe.We have twelve different Professional Podcasts on all the things you like. New favorite shows drop each day only on the UNTOLD RADIO NETWORK.To find out more about Barnaby Jones and his team, (Cryptids, Anomalies, and the Paranormal Society) visit their website www.WisconsinCAPS.comMake sure you share and Subscribe to the CAPS YouTube Channel as wellhttps://www.youtube.com/channel/UCs7ifB9Ur7x2C3VqTzVmjNQ

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: C - Wed Bible StudyType: Gospel MeetingSpeaker: Mark RobertsGospel meeting Wednesday evening sermon Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: D - Gospel MeetingType: Gospel MeetingSpeaker: Mark RobertsTuesday night gospel meeting sermon Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: D - Gospel MeetingType: Gospel MeetingSpeaker: Mark RobertsMonday night gospel meeting sermon Mark Roberts

Click here for the reading materialClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: B - Sun AM WorshipType: Gospel MeetingSpeaker: Mark RobertsSunday morning sermon Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: B - Sun PM WorshipType: Gospel MeetingSpeaker: Mark RobertsSunday evening sermon Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: A - Sun Bible StudyType: Gospel MeetingSpeaker: Mark RobertsSunday morning bible class Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: B - Sun AM WorshipType: Gospel MeetingSpeaker: Mark RobertsSunday morning sermon Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: A - Sun Bible StudyType: Gospel MeetingSpeaker: Mark RobertsSunday morning bible class Mark Roberts

Series: Ready ....Set....Grow! - Gospel Meeting Fall 2025Service: B - Sun PM WorshipType: Gospel MeetingSpeaker: Mark RobertsSunday evening sermon Mark Roberts

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the reading materialClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the reading materialClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the reading materialClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.

Grammy-winning artist, actor, and producer Scott Hoying—best known as a founding member of Grammy award group Pentatonix—joins The Film Hustler Podcast alongside Scott's husband and creative partner Mark Hoying.Together, they talk about their love of music, songwriting, and co-authoring their heartfelt children's books, How Lucky Am I? and How Proud Am I?. Scott dives into his solo music, including social media darlings “Flaunt It” and “Pray,” and shares the story behind Pentatonix's viral “White Winter Hymnal” video, featured in his Netflix film, Meet Me Next Christmas.They also discuss Mark and Scott's roles in founding Citizen Queen, the powerhouse girl group reimagining the modern vocal ensemble.From viral harmonies and streaming hits to bestselling books and hands-on producing, Scott Hoying's journey—alongside Mark—is one of creativity, connection, and taking chances. You won't want to miss this one.

Click here for the SermonClicking here will take you to our webpageClick here to contact usWelcome to the Westside church's special Monday Morning Coffee podcast with Mark Roberts. Mark is a disciple, a husband, father and grand dad, as well as a certified coffee geek, fan of CS Lewis' writings and he loves his big red Jeep. He's also the preacher for Westside church.